(A–F) Changes of B-cell numbers and B-cell related biomarkers.

Slides:

Advertisements

Similar presentations

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Advertisements

Multivariable model of abatacept retention in biologic-naïve patients.

The GR dimer in stromal cells mediates the induction of genes of anti-inflammatory macrophages after DEX treatment in serum transfer-induced arthritis.

Multivariable model of abatacept retention by RF and anti-CCP status in biologic-naïve patients with or without radiographic erosion at baseline. Multivariable.

(A) EULAR response based on DAS28 (ESR, otherwise CRP) and (B) Boolean remission, at 6 months in patients treated with abatacept as a first-line biologic.

(A) Lequesne index and quadriceps strength of patients with knee OA

Detection of lysine carbamylation and arginine citrullination in IgGH from bronchiectasis and rheumatoid arthritis patients. a) Schematic model of IgGH.

Management of hyperuricaemia in patients with gout according to the European League Against Rheumatism recommendations. Management of hyperuricaemia in.

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

Percentage of patients achieving EULAR response

Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)

The patient profiles presented to rheumatologists in the discrete choice experiment (DCE). aCCP, anti-cyclic citrullinated peptide; DAS28, 28-joint Disease.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

(A) Reduction of circulating stromal cell-derived factor (SDF)-1 levels over time in patients with rheumatoid arthritis (RA) and ankylosing spondylitis.

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Figure 1 Total IgG, IgA, and IgM levels and hypo-Ig prevalence during RTX treatment Total IgG, IgA, and IgM levels and hypo-Ig prevalence during RTX treatment.

Treatment strategy. Treatment strategy. For every patient, changes of treatment were analysed per change, for up to five subsequent therapeutic changes.

Algorithm based on the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Algorithm based on the ASAS-EULAR recommendations for.

Multivariate analysis for SRP after 3 years in patients with moderate disease activity despite MTX treatment. Multivariate analysis for SRP after 3 years.

IL-6-dependent changes in preclinical phase of arthritis in gp130F759.

The earliest pathological changes of arthritis in gp130F759 develop at 5 months of age. The earliest pathological changes of arthritis in gp130F759 develop.

Step-down efficacy through week 48: categorical CDAI state DMARD-IR (RA-BEAM, RA-BUILD, RA-BEACON) analysis set. Step-down efficacy through week 48: categorical.

Coronal section through the distal interphalangeal joint of the left middle finger shown in figure 2. Coronal section through the distal interphalangeal.

OVA-specific and InvaplexNAT-specific serum IgG endpoint titers in mice after intranasal immunization with OVA alone or OVA combined with InvaplexAR, InvaplexNAT,

Least squares mean changes from baseline (and 95% CIs) at month three for (A) HAQ-DI, (B) FACIT-F and (C) SF-36 physical functioning domain observed in.

Achilles tendon tear. Achilles tendon tear. (A) Longitudinal and (B) transverse images of the calf: at the middle third of the left Achilles tendon there.

Heterogeneity of TCRβ repertoire in autoimmune diseases.

Study design. *Randomisation stratified by corticosteroid use at baseline. Study design. *Randomisation stratified by corticosteroid use at baseline. DAS28-CRP,

The proportions (and 95% CIs) of anti-CCP+/RF+, anti-CCP+/RF- anti-CCP-/RF+ and anti-CCP-/RF- patients receiving tofacitinib 5 or 10 mg two times a day.

The proportions (and 95% CIs) of anti-CCP+/RF+, anti-CCP+/RF-, anti-CCP-/RF+ and anti-CCP-/RF- patients receiving tofacitinib 5 or 10 mg two times a day.

Reduction of strength loss after intervention described as averaged differences (visit 4 compared with visit 1) of the baseline corrected time points 0hours.

“Tennis Leg”. “Tennis Leg”. Serial Longitudinal images of the calf: (1) There is a well localised hypoechoic collection (C) interposed between the medial.

February 1998 (age 14 years and 8 months).

Kaplan-Meier survival plot for primary endpoint of arthritis development. Kaplan-Meier survival plot for primary endpoint of arthritis development. Arthritis-free.

Increased numbers of LDGs in association with disease activity and low complement levels in patients with SLE. Numbers of LDGs were determined by flow.

Calcium pyrophosphate dihydrate crystals extracted from the synovial fluid of a patient with pseudogout viewed under polarised light microscopy. Calcium.

(A) JIA-ACR30/50/70/90 response rates by visit in part 1.

Associations between the ‘% of patients that ever used a bDMARD’ and the ‘composite score clinical criteria’, ‘composite score access to medication’ and.

Frequency distribution of the number of fulfilled classification criteria for RA (ACR 1987) in relation to the proportion of positive anti-CCP antibodies.

Changes over time in DAS 28 (A), SLEDAI (B), glucocorticoid dose (C) and EULAR response (D) in patients with rhupus treated by anti-TNF-α. Box plot (median,

(A) Knees showing marked osteophytes grade III and enthesophytes at the tibial tubercle grade II. (B) Grade III osteophyte around the carpo-metacarpal.

Typical mean functional strength (where maximum function scores 5, and minimum scores zero; arithmetic mean of several activities plotted) against serum.

Fluoroscopic image of the suprascapular nerve block injection.

Effect sizes (95% CI) of clinical variables per treatment group of studies directly comparing different dosages/routes. Effect sizes (95% CI) of clinical.

Mean disease activity score based on a 28-joint count (DAS28 (ESR)) (A), Clinical Disease Activity Index (CDAI) score (B) and Simplified Disease Activity.

(A) Sensitivity and specificity values seen in the 827 patients with HSP versus the other forms of childhood vasculitides (c-PAN 150, c-WG 60, c-TA 87).

Serial determinations of both anti-chromatin and anti-dsDNA antibodies in a patient who developed lupus nephropathy during the study period, showing that.

Endothelial cell density change to baseline at 60 after surgery plotted against phacoemulsification time in groups Balanced Salt Solution Plus (BSS-Plus)

ACPA and RF titres in patients with early RA treated with abatacept+MTX compared with MTX alone. ACPA and RF titres in patients with early RA treated with.

Status of tapering in the first year of follow-up.

Ultrasonographic picture of second metatarsophalangeal joint with synovitis (panel A) and without synovitis (panel B). a, metatarsal head; b, base of.

Dual-energy CT images. Dual-energy CT images. Arrows indicate MSU deposition (MSU deposits colour coded in green). (A) Subject accuracy study with acute.

Diagram of the tendons and ligaments of the fingers showing the potential windows at the interphalangeal joints and the lack of a window at the metacarpophalangeal.

Seven weeks after presentation: scattered posterior pole intra-retinal haemorrhages and cotton wool spots; right eye (A) and left eye (B). Seven weeks.

Statistically significant correlation between the expression of FRP2 or BLT1 in monocytes and different parameters such as ESR (p: 0,0166; r: -0,434),

Changes over time of the daily prednisone dose in patients that responded to anakinra. Changes over time of the daily prednisone dose in patients that.

Patient disposition. *n=1 patient took prohibited concomitant medication due to an adverse event and was discontinued from the study. Patient disposition.

Generation and affinity maturation of anti-tenascin-C antibodies.

(A) Bar chart presenting the most significantly upregulated and downregulated entities by fold change (FC). (A) Bar chart presenting the most significantly.

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Per cent change in lumbar spinal bone mineral density (BMD) at 12 months from baseline in all patients (A), patients stratified by baseline use of glucocorticoid.

Kaplan–Meier curves of relapse-free survival of the CAR-T cohort (left) and the HCT cohort (right) of 8 CAR-T patients and 12 HCT patients whose preceding.

Average annual price for csDMARDs (A) and bDMARDs (B) per country in international dollars (light blue) and in euros (dark blue), prices first quarter.

The right hand of the same patient as in figure 1, photographed from the ulnar side, showing dorsolateral nodes in profile on the index and ring fingers,

(A) A barium follow-through showing a dilated oesophagus with markedly dilated loops of the small bowel; (B) abdominal computed tomography showing dilated,

Defining the mode of action of neutralising anti-tenascin-C antibodies

Antibody treatment ameliorates inflammation in experimental arthritis.

Baker’s cyst (photomontage).

Associations between ‘GDP per capita (IntI$)’ and ‘days to work at the minimum wage to cover 30 days of treatment with a bDMARD’ with clinical outcomes.

Associations between ‘GDP per capita’ and ‘days to work at the minimum wage to cover 30 days of treatment with a bDMARD’ with ‘% bDMARD use’. bDMARD, biological.

Presentation transcript:

(A–F) Changes of B-cell numbers and B-cell related biomarkers. (A–F) Changes of B-cell numbers and B-cell related biomarkers. Total number of B cells (Log10 109/L; A), serum IgA rheumatoid factor (RF) (Log kU/L; B), IgM-RF (Log kU/L; C), IgG-RF (Log kU/L; D); IgM (Log g/L; E), and anti-citrullinated cyclic peptide (CCP) test levels (Log kAU/L; F) from baseline to follow-up time points (days) measured in the individuals treated with placebo (red) and rituximab (green). The thin lines represent changes in the individuals and the thick lines represent the mean numbers/levels for each group. Vertical lines represent the 95% CIs. Statistically significant differences (shown p values) between the two treatment groups were found for all values depicted here, except for the serum IgG-RF and anti-CCP levels. Danielle M Gerlag et al. Ann Rheum Dis 2019;78:179-185 ©2019 by BMJ Publishing Group Ltd and European League Against Rheumatism